{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:18:37Z","timestamp":1778923117000,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":629,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI18C0480"],"award-info":[{"award-number":["HI18C0480"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jtct.2021.05.024","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T12:38:35Z","timestamp":1622464715000},"page":"774.e1-774.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients"],"prefix":"10.1016","volume":"27","author":[{"given":"Byung-Sik","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myungshin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.05.024_bib0001","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0002","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Swedish Acute Leukemia Registry G. Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0003","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0004","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/cancers10070232","article-title":"Bridging strategies to allogeneic transplant for older AML patients","volume":"10","author":"Hecker","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2021.05.024_bib0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.blre.2017.07.002","article-title":"The who, how and why: allogeneic transplant for acute myeloid leukemia in patients older than 60years","volume":"31","author":"Wall","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2021.05.024_bib0006","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0007","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.beha.2013.10.011","article-title":"Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia","volume":"26","author":"Champlin","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"19","key":"10.1016\/j.jtct.2021.05.024_bib0008","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0009","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/sj.leu.2403770","article-title":"The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison","volume":"19","author":"Mohty","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.05.024_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbmt.2010.07.013","article-title":"Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission","volume":"17","author":"Kurosawa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0012","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1200\/JCO.2007.15.5184","article-title":"Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0013","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0014","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/bmt.2015.180","article-title":"In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?","volume":"50","author":"Peffault de Latour","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0015","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.bbmt.2019.06.031","volume":"25","author":"Shimoni","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0016","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"23","author":"D'Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0017","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exphem.2017.11.001","article-title":"T-cell-replete haploidentical transplantation in acute myeloid leukemia","volume":"58","author":"Castagna","year":"2018","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2015.08.029","volume":"22","author":"Blaise","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41409-018-0126-4","article-title":"Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older","volume":"53","author":"Bashey","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0021","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbmt.2018.02.002","article-title":"HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison","volume":"24","author":"Devillier","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0022","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/cancers10090340","article-title":"Autologous transplantation for older adults with AML","volume":"10","author":"Mueller","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2021.05.024_bib0023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/cancers12010059","article-title":"Is there still a role for autologous stem cell transplantation for the treatment of acute myeloid leukemia?","volume":"12","author":"Ferrara","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2021.05.024_bib0024","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0025","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0026","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.23576","article-title":"Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status","volume":"88","author":"Yoon","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0027","doi-asserted-by":"crossref","first-page":"41590","DOI":"10.18632\/oncotarget.15295","article-title":"Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types","volume":"8","author":"Yoon","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2021.05.024_bib0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12185-010-0649-y","article-title":"Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and\/or co-morbidities","volume":"92","author":"Lee","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2014.09.029","article-title":"A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia","volume":"21","author":"Yahng","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.05.024_bib0031","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2013.03.013","article-title":"Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia","volume":"19","author":"Yoon","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0032","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1038\/bcj.2015.61","article-title":"Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2021.05.024_bib0033","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bbmt.2019.05.033","article-title":"WT1 measurable residual disease assay in patients with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation: optimal time points, thresholds, and candidates","volume":"25","author":"Cho","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0034","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0035","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"O'Donnell","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtct.2021.05.024_bib0036","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbmt.2014.12.035","article-title":"2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series","volume":"21","author":"Pavletic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0037","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0038","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.05.024_bib0039","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0041","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.bbmt.2012.04.008","article-title":"Comparison of allogeneic stem cell transplantation from familial-mismatched\/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia","volume":"18","author":"Cho","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0042","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbmt.2017.05.025","article-title":"Reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin for hematopoietic cell transplantation from unrelated or haploidentical family donors in patients with acute myeloid leukemia in remission","volume":"23","author":"Lee","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0043","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jtct.2021.05.024_bib0044","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/bloodadvances.2019000682","article-title":"Impact of gammadelta T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"3","author":"Arruda","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.05.024_bib0045","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.05.024_bib0046","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1200\/JCO.2008.21.0674","article-title":"Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML Intergroup","volume":"27","author":"Prebet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0047","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3\u2013internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council Report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0048","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2018.09.032","article-title":"Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia","volume":"25","author":"Veltri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.05.024_bib0049","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.05.024_bib0050","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0051","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.beha.2019.101109","article-title":"Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"32","author":"Appelbaum","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2021.05.024_bib0052","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm9010039","article-title":"Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients","volume":"9","author":"Greiner","year":"2019","journal-title":"J Clin Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672100943X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672100943X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:59:34Z","timestamp":1778921974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672100943X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S266663672100943X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}